STOCK TITAN

[424B2] MicroSectors Energy 3x Leveraged ETNs Prospectus Supplement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
424B2
Rhea-AI Filing Summary

Bank of Montreal (Series K) is issuing US$5.518 million of Autocallable Barrier Notes with Contingent Coupons, maturing 23 July 2026 and linked to the American depositary receipts of Novo Nordisk A/S (ticker "NVO").

The notes pay a monthly contingent coupon of 1.0583% (≈12.70% p.a.) only if, on the related Observation Date, the ADR closes at or above the Coupon Barrier of $44.60 (60 % of the $74.34 Initial Level). If this test fails, that month’s coupon is skipped.

Automatic redemption can occur on any Observation Date from 18 December 2025 onward if the ADR closes above the Initial Level (100 %). Investors would then receive par plus the due coupon on the next payment date and the notes terminate.

If the notes remain outstanding to maturity and a Trigger Event occurs (Final Level < $44.60), principal is reduced 1 % for every 1 % decline in the ADR, potentially down to zero. If no Trigger Event occurs, holders receive full principal.

Key structural details:

  • Issue price: 100 % of par; estimated initial value: $964.18 per $1,000.
  • Agent’s commission: 2.15 %; proceeds to BMO: 97.85 %.
  • Denomination: $1,000; the notes will not be listed on any exchange.
  • All payments are subject to Bank of Montreal’s credit risk; the notes are unsecured and unsubordinated.

The product is intended for yield-seeking investors comfortable with (1) credit exposure to BMO, (2) equity downside risk to NVO below 60 % of the Initial Level, and (3) limited liquidity due to the absence of an exchange listing.

La Bank of Montreal (Serie K) emette Note Autocallable con Barriera e Cedole Contingenti per un importo di 5,518 milioni di dollari USA, con scadenza il 23 luglio 2026, collegate agli American Depositary Receipts di Novo Nordisk A/S (ticker "NVO").

Le note pagano una cedola contingente mensile dell'1,0583% (circa 12,70% annuo) solo se, nella relativa Data di Osservazione, l'ADR chiude al livello o sopra la Barriera di Cedola di 44,60$ (il 60% del livello iniziale di 74,34$). In caso contrario, la cedola di quel mese non viene corrisposta.

La redenzione automatica può avvenire in qualsiasi Data di Osservazione a partire dal 18 dicembre 2025, se l'ADR chiude sopra il livello iniziale (100%). In tal caso, gli investitori ricevono il valore nominale più la cedola dovuta alla data di pagamento successiva e le note terminano.

Se le note restano in essere fino alla scadenza e si verifica un Evento Trigger (livello finale < 44,60$), il capitale viene ridotto dell'1% per ogni 1% di calo dell'ADR, potenzialmente fino a zero. Se non si verifica alcun Evento Trigger, i detentori ricevono il capitale pieno.

Dettagli strutturali principali:

  • Prezzo di emissione: 100% del valore nominale; valore iniziale stimato: 964,18$ per ogni 1.000$ nominali.
  • Commissione dell'agente: 2,15%; proventi netti per BMO: 97,85%.
  • Taglio: 1.000$; le note non saranno quotate in alcun mercato regolamentato.
  • Tutti i pagamenti sono soggetti al rischio di credito della Bank of Montreal; le note sono non garantite e non subordinate.

Il prodotto è destinato a investitori alla ricerca di rendimento che accettano (1) il rischio di credito verso BMO, (2) il rischio di ribasso azionario di NVO sotto il 60% del livello iniziale e (3) una liquidità limitata dovuta alla mancata quotazione in borsa.

Bank of Montreal (Serie K) está emitiendo Notas Autollamables con Barrera y Cupones Contingentes por un monto de 5,518 millones de dólares estadounidenses, con vencimiento el 23 de julio de 2026, vinculadas a los American Depositary Receipts de Novo Nordisk A/S (ticker "NVO").

Las notas pagan un cupón contingente mensual del 1.0583% (aproximadamente 12.70% anual) solo si, en la Fecha de Observación correspondiente, el ADR cierra en o por encima de la Barrera de Cupón de $44.60 (60% del Nivel Inicial de $74.34). Si esta condición no se cumple, el cupón de ese mes se omite.

La redención automática puede ocurrir en cualquier Fecha de Observación a partir del 18 de diciembre de 2025 si el ADR cierra por encima del Nivel Inicial (100%). En ese caso, los inversores recibirán el valor nominal más el cupón correspondiente en la siguiente fecha de pago y las notas finalizarán.

Si las notas permanecen hasta el vencimiento y ocurre un Evento Disparador (Nivel Final < $44.60), el principal se reduce un 1% por cada 1% de caída en el ADR, potencialmente hasta cero. Si no ocurre ningún Evento Disparador, los tenedores reciben el principal completo.

Detalles estructurales clave:

  • Precio de emisión: 100% del valor nominal; valor inicial estimado: $964.18 por cada $1,000 nominales.
  • Comisión del agente: 2.15%; ingresos para BMO: 97.85%.
  • Denominación: $1,000; las notas no estarán listadas en ninguna bolsa.
  • Todos los pagos están sujetos al riesgo crediticio de Bank of Montreal; las notas no están garantizadas ni subordinadas.

El producto está dirigido a inversores que buscan rendimiento y que están cómodos con (1) la exposición crediticia a BMO, (2) el riesgo de caída del equity de NVO por debajo del 60% del Nivel Inicial y (3) la liquidez limitada debido a la ausencia de cotización en bolsa.

뱅크 오브 몬트리올(시리즈 K)은 2026년 7월 23일 만기이며 Novo Nordisk A/S(티커 "NVO")의 미국예탁증서(ADR)에 연동된 미화 5,518만 달러 규모의 자동상환형 배리어 노트(Autocallable Barrier Notes)와 조건부 쿠폰을 발행합니다.

이 노트는 해당 관찰일에 ADR 종가가 쿠폰 배리어인 44.60달러(초기 수준 74.34달러의 60%) 이상일 경우에만 월 1.0583%(연 약 12.70%)의 조건부 쿠폰을 지급합니다. 만약 이 조건을 충족하지 못하면 해당 월의 쿠폰은 지급되지 않습니다.

자동 상환은 2025년 12월 18일부터 시작되는 모든 관찰일에 ADR 종가가 초기 수준(100%) 이상일 경우 발생할 수 있습니다. 이 경우 투자자는 다음 지급일에 원금과 해당 쿠폰을 받고 노트는 종료됩니다.

노트가 만기까지 유지되고 트리거 이벤트(최종 수준 < 44.60달러)가 발생하면, 원금은 ADR 하락률 1%당 1%씩 감소하며 최악의 경우 0까지 줄어들 수 있습니다. 트리거 이벤트가 발생하지 않으면 투자자는 원금을 전액 상환받습니다.

주요 구조적 세부사항:

  • 발행가: 액면가의 100%; 초기 예상 가치: 1,000달러당 964.18달러.
  • 대리인 수수료: 2.15%; BMO 수익: 97.85%.
  • 액면가: 1,000달러; 노트는 어떤 거래소에도 상장되지 않습니다.
  • 모든 지급은 뱅크 오브 몬트리올의 신용 위험에 노출되며, 노트는 무담보 및 비후순위입니다.

이 상품은 (1) BMO에 대한 신용 노출, (2) NVO 주가가 초기 수준의 60% 이하로 하락할 위험, (3) 거래소 상장 부재로 인한 제한된 유동성을 감수할 수 있는 수익 추구 투자자를 위한 것입니다.

La Banque de Montréal (série K) émet des Notes à Barrière Autocallables avec Coupons Conditionnels pour un montant de 5,518 millions de dollars US, arrivant à échéance le 23 juillet 2026, liées aux American Depositary Receipts de Novo Nordisk A/S (symbole "NVO").

Les notes versent un coupon conditionnel mensuel de 1,0583 % (environ 12,70 % par an) uniquement si, à la Date d'Observation correspondante, l'ADR clôture au-dessus ou à la Barrière de Coupon de 44,60 $ (60 % du niveau initial de 74,34 $). Si ce test échoue, le coupon de ce mois est omis.

Un rachat automatique peut intervenir à toute Date d'Observation à partir du 18 décembre 2025 si l'ADR clôture au-dessus du Niveau Initial (100 %). Les investisseurs recevront alors le pair plus le coupon dû à la prochaine date de paiement et les notes prendront fin.

Si les notes restent en circulation jusqu'à l'échéance et qu'un événement déclencheur survient (niveau final < 44,60 $), le capital est réduit de 1 % pour chaque baisse de 1 % de l'ADR, potentiellement jusqu'à zéro. Si aucun événement déclencheur ne survient, les porteurs reçoivent le capital intégral.

Détails structurels clés :

  • Prix d'émission : 100 % du pair ; valeur initiale estimée : 964,18 $ pour 1 000 $ de nominal.
  • Commission de l'agent : 2,15 % ; produit net pour BMO : 97,85 %.
  • Nominal : 1 000 $ ; les notes ne seront pas cotées en bourse.
  • Tous les paiements sont soumis au risque de crédit de la Banque de Montréal ; les notes sont non garanties et non subordonnées.

Ce produit s'adresse aux investisseurs recherchant du rendement et acceptant (1) une exposition au risque de crédit de BMO, (2) un risque de baisse de l'action NVO en dessous de 60 % du niveau initial, et (3) une liquidité limitée due à l'absence de cotation en bourse.

Die Bank of Montreal (Serie K) gibt Autocallable Barrier Notes mit bedingten Coupons im Umfang von 5,518 Mio. USD aus, mit Fälligkeit am 23. Juli 2026, die an die American Depositary Receipts von Novo Nordisk A/S (Ticker "NVO") gekoppelt sind.

Die Notes zahlen einen monatlichen bedingten Coupon von 1,0583 % (ca. 12,70 % p.a.) nur, wenn der ADR am jeweiligen Beobachtungstag auf oder über der Coupon-Barriere von 44,60 USD (60 % des Anfangsniveaus von 74,34 USD) schließt. Wird diese Bedingung nicht erfüllt, entfällt der Coupon für diesen Monat.

Eine automatische Rückzahlung kann an jedem Beobachtungstag ab dem 18. Dezember 2025 erfolgen, sofern der ADR über dem Anfangsniveau (100 %) schließt. Investoren erhalten dann den Nennwert zuzüglich des fälligen Coupons am nächsten Zahlungstermin und die Notes enden.

Bleiben die Notes bis zur Fälligkeit bestehen und tritt ein Trigger-Ereignis ein (Endniveau < 44,60 USD), wird das Kapital um 1 % für jeden 1 % Rückgang des ADR reduziert, möglicherweise bis auf null. Erfolgt kein Trigger-Ereignis, erhalten die Inhaber den vollen Kapitalbetrag zurück.

Wesentliche strukturelle Details:

  • Ausgabepreis: 100 % des Nennwerts; geschätzter Anfangswert: 964,18 USD pro 1.000 USD Nennwert.
  • Agenturkommission: 2,15 %; Erlöse für BMO: 97,85 %.
  • Nennwert: 1.000 USD; die Notes werden nicht an einer Börse notiert.
  • Alle Zahlungen unterliegen dem Kreditrisiko der Bank of Montreal; die Notes sind unbesichert und nicht nachrangig.

Das Produkt richtet sich an renditeorientierte Anleger, die mit (1) Kreditrisiko gegenüber BMO, (2) dem Aktienabwärtsrisiko von NVO unter 60 % des Anfangsniveaus und (3) eingeschränkter Liquidität aufgrund fehlender Börsennotierung leben können.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: 12.70 % coupon looks attractive, but principal is at risk below a 40 % drawdown; impact on BMO equity is negligible.

The supplement outlines a standard autocallable barrier structure. The coupon rate of ≈12.70 % is high relative to short-term rates, reflecting the double risk layer: (i) 100 % credit exposure to BMO and (ii) equity risk to Novo Nordisk ADRs. The 60 % trigger provides a 40 % buffer, but a sharp decline in NVO would translate into a dollar-for-dollar loss of principal at maturity. Automatic redemption mechanics shorten duration if NVO trades above $74.34, capping upside for investors and lowering BMO’s exposure. The estimated initial value of $964.18 indicates a ~3.6 % issuer margin after commissions—typical for retail structured notes. Overall market impact is minimal; the US$5.5 million size is immaterial to BMO’s balance sheet.

TL;DR: High coupon is contingent; investors face credit, market and liquidity risks with no principal protection.

The notes concentrate several risks: (1) Credit risk: payments rely on BMO’s ability to pay; (2) Market risk: a 40 % fall in NVO triggers linear capital loss; (3) Liquidity risk: no exchange listing may force secondary sales at significant discounts; (4) Valuation risk: initial value is $35.82 below issue price, meaning an immediate mark-to-market drag. While coupons look compelling, they are not guaranteed and may cease entirely in prolonged downturns. For sophisticated investors only; overall market significance is low, so I classify impact as neutral.

La Bank of Montreal (Serie K) emette Note Autocallable con Barriera e Cedole Contingenti per un importo di 5,518 milioni di dollari USA, con scadenza il 23 luglio 2026, collegate agli American Depositary Receipts di Novo Nordisk A/S (ticker "NVO").

Le note pagano una cedola contingente mensile dell'1,0583% (circa 12,70% annuo) solo se, nella relativa Data di Osservazione, l'ADR chiude al livello o sopra la Barriera di Cedola di 44,60$ (il 60% del livello iniziale di 74,34$). In caso contrario, la cedola di quel mese non viene corrisposta.

La redenzione automatica può avvenire in qualsiasi Data di Osservazione a partire dal 18 dicembre 2025, se l'ADR chiude sopra il livello iniziale (100%). In tal caso, gli investitori ricevono il valore nominale più la cedola dovuta alla data di pagamento successiva e le note terminano.

Se le note restano in essere fino alla scadenza e si verifica un Evento Trigger (livello finale < 44,60$), il capitale viene ridotto dell'1% per ogni 1% di calo dell'ADR, potenzialmente fino a zero. Se non si verifica alcun Evento Trigger, i detentori ricevono il capitale pieno.

Dettagli strutturali principali:

  • Prezzo di emissione: 100% del valore nominale; valore iniziale stimato: 964,18$ per ogni 1.000$ nominali.
  • Commissione dell'agente: 2,15%; proventi netti per BMO: 97,85%.
  • Taglio: 1.000$; le note non saranno quotate in alcun mercato regolamentato.
  • Tutti i pagamenti sono soggetti al rischio di credito della Bank of Montreal; le note sono non garantite e non subordinate.

Il prodotto è destinato a investitori alla ricerca di rendimento che accettano (1) il rischio di credito verso BMO, (2) il rischio di ribasso azionario di NVO sotto il 60% del livello iniziale e (3) una liquidità limitata dovuta alla mancata quotazione in borsa.

Bank of Montreal (Serie K) está emitiendo Notas Autollamables con Barrera y Cupones Contingentes por un monto de 5,518 millones de dólares estadounidenses, con vencimiento el 23 de julio de 2026, vinculadas a los American Depositary Receipts de Novo Nordisk A/S (ticker "NVO").

Las notas pagan un cupón contingente mensual del 1.0583% (aproximadamente 12.70% anual) solo si, en la Fecha de Observación correspondiente, el ADR cierra en o por encima de la Barrera de Cupón de $44.60 (60% del Nivel Inicial de $74.34). Si esta condición no se cumple, el cupón de ese mes se omite.

La redención automática puede ocurrir en cualquier Fecha de Observación a partir del 18 de diciembre de 2025 si el ADR cierra por encima del Nivel Inicial (100%). En ese caso, los inversores recibirán el valor nominal más el cupón correspondiente en la siguiente fecha de pago y las notas finalizarán.

Si las notas permanecen hasta el vencimiento y ocurre un Evento Disparador (Nivel Final < $44.60), el principal se reduce un 1% por cada 1% de caída en el ADR, potencialmente hasta cero. Si no ocurre ningún Evento Disparador, los tenedores reciben el principal completo.

Detalles estructurales clave:

  • Precio de emisión: 100% del valor nominal; valor inicial estimado: $964.18 por cada $1,000 nominales.
  • Comisión del agente: 2.15%; ingresos para BMO: 97.85%.
  • Denominación: $1,000; las notas no estarán listadas en ninguna bolsa.
  • Todos los pagos están sujetos al riesgo crediticio de Bank of Montreal; las notas no están garantizadas ni subordinadas.

El producto está dirigido a inversores que buscan rendimiento y que están cómodos con (1) la exposición crediticia a BMO, (2) el riesgo de caída del equity de NVO por debajo del 60% del Nivel Inicial y (3) la liquidez limitada debido a la ausencia de cotización en bolsa.

뱅크 오브 몬트리올(시리즈 K)은 2026년 7월 23일 만기이며 Novo Nordisk A/S(티커 "NVO")의 미국예탁증서(ADR)에 연동된 미화 5,518만 달러 규모의 자동상환형 배리어 노트(Autocallable Barrier Notes)와 조건부 쿠폰을 발행합니다.

이 노트는 해당 관찰일에 ADR 종가가 쿠폰 배리어인 44.60달러(초기 수준 74.34달러의 60%) 이상일 경우에만 월 1.0583%(연 약 12.70%)의 조건부 쿠폰을 지급합니다. 만약 이 조건을 충족하지 못하면 해당 월의 쿠폰은 지급되지 않습니다.

자동 상환은 2025년 12월 18일부터 시작되는 모든 관찰일에 ADR 종가가 초기 수준(100%) 이상일 경우 발생할 수 있습니다. 이 경우 투자자는 다음 지급일에 원금과 해당 쿠폰을 받고 노트는 종료됩니다.

노트가 만기까지 유지되고 트리거 이벤트(최종 수준 < 44.60달러)가 발생하면, 원금은 ADR 하락률 1%당 1%씩 감소하며 최악의 경우 0까지 줄어들 수 있습니다. 트리거 이벤트가 발생하지 않으면 투자자는 원금을 전액 상환받습니다.

주요 구조적 세부사항:

  • 발행가: 액면가의 100%; 초기 예상 가치: 1,000달러당 964.18달러.
  • 대리인 수수료: 2.15%; BMO 수익: 97.85%.
  • 액면가: 1,000달러; 노트는 어떤 거래소에도 상장되지 않습니다.
  • 모든 지급은 뱅크 오브 몬트리올의 신용 위험에 노출되며, 노트는 무담보 및 비후순위입니다.

이 상품은 (1) BMO에 대한 신용 노출, (2) NVO 주가가 초기 수준의 60% 이하로 하락할 위험, (3) 거래소 상장 부재로 인한 제한된 유동성을 감수할 수 있는 수익 추구 투자자를 위한 것입니다.

La Banque de Montréal (série K) émet des Notes à Barrière Autocallables avec Coupons Conditionnels pour un montant de 5,518 millions de dollars US, arrivant à échéance le 23 juillet 2026, liées aux American Depositary Receipts de Novo Nordisk A/S (symbole "NVO").

Les notes versent un coupon conditionnel mensuel de 1,0583 % (environ 12,70 % par an) uniquement si, à la Date d'Observation correspondante, l'ADR clôture au-dessus ou à la Barrière de Coupon de 44,60 $ (60 % du niveau initial de 74,34 $). Si ce test échoue, le coupon de ce mois est omis.

Un rachat automatique peut intervenir à toute Date d'Observation à partir du 18 décembre 2025 si l'ADR clôture au-dessus du Niveau Initial (100 %). Les investisseurs recevront alors le pair plus le coupon dû à la prochaine date de paiement et les notes prendront fin.

Si les notes restent en circulation jusqu'à l'échéance et qu'un événement déclencheur survient (niveau final < 44,60 $), le capital est réduit de 1 % pour chaque baisse de 1 % de l'ADR, potentiellement jusqu'à zéro. Si aucun événement déclencheur ne survient, les porteurs reçoivent le capital intégral.

Détails structurels clés :

  • Prix d'émission : 100 % du pair ; valeur initiale estimée : 964,18 $ pour 1 000 $ de nominal.
  • Commission de l'agent : 2,15 % ; produit net pour BMO : 97,85 %.
  • Nominal : 1 000 $ ; les notes ne seront pas cotées en bourse.
  • Tous les paiements sont soumis au risque de crédit de la Banque de Montréal ; les notes sont non garanties et non subordonnées.

Ce produit s'adresse aux investisseurs recherchant du rendement et acceptant (1) une exposition au risque de crédit de BMO, (2) un risque de baisse de l'action NVO en dessous de 60 % du niveau initial, et (3) une liquidité limitée due à l'absence de cotation en bourse.

Die Bank of Montreal (Serie K) gibt Autocallable Barrier Notes mit bedingten Coupons im Umfang von 5,518 Mio. USD aus, mit Fälligkeit am 23. Juli 2026, die an die American Depositary Receipts von Novo Nordisk A/S (Ticker "NVO") gekoppelt sind.

Die Notes zahlen einen monatlichen bedingten Coupon von 1,0583 % (ca. 12,70 % p.a.) nur, wenn der ADR am jeweiligen Beobachtungstag auf oder über der Coupon-Barriere von 44,60 USD (60 % des Anfangsniveaus von 74,34 USD) schließt. Wird diese Bedingung nicht erfüllt, entfällt der Coupon für diesen Monat.

Eine automatische Rückzahlung kann an jedem Beobachtungstag ab dem 18. Dezember 2025 erfolgen, sofern der ADR über dem Anfangsniveau (100 %) schließt. Investoren erhalten dann den Nennwert zuzüglich des fälligen Coupons am nächsten Zahlungstermin und die Notes enden.

Bleiben die Notes bis zur Fälligkeit bestehen und tritt ein Trigger-Ereignis ein (Endniveau < 44,60 USD), wird das Kapital um 1 % für jeden 1 % Rückgang des ADR reduziert, möglicherweise bis auf null. Erfolgt kein Trigger-Ereignis, erhalten die Inhaber den vollen Kapitalbetrag zurück.

Wesentliche strukturelle Details:

  • Ausgabepreis: 100 % des Nennwerts; geschätzter Anfangswert: 964,18 USD pro 1.000 USD Nennwert.
  • Agenturkommission: 2,15 %; Erlöse für BMO: 97,85 %.
  • Nennwert: 1.000 USD; die Notes werden nicht an einer Börse notiert.
  • Alle Zahlungen unterliegen dem Kreditrisiko der Bank of Montreal; die Notes sind unbesichert und nicht nachrangig.

Das Produkt richtet sich an renditeorientierte Anleger, die mit (1) Kreditrisiko gegenüber BMO, (2) dem Aktienabwärtsrisiko von NVO unter 60 % des Anfangsniveaus und (3) eingeschränkter Liquidität aufgrund fehlender Börsennotierung leben können.

 

Registration Statement No.333-285508
Filed Pursuant to Rule 424(b)(2)

 


Pricing Supplement dated June 17, 2025 to the Prospectus dated March 25, 2025,
the Prospectus Supplement dated March 25, 2025 and the Product Supplement dated March 25, 2025

 

 

 

US$5,518,000
Senior Medium-Term Notes, Series K
Autocallable Barrier Notes with Contingent Coupons due July 23, 2026
Linked to the American depositary receipts of Novo Nordisk A/S

 

·The notes are designed for investors who are seeking monthly contingent periodic interest payments (as described in more detail below), as well as a return of principal if the closing level of the American depositary receipts of Novo Nordisk A/S (the “Reference Asset”) on any monthly Observation Date beginning in December 2025 is greater than 100% of its Initial Level (the “Call Level”). Investors should be willing to have their notes automatically redeemed prior to maturity, be willing to forego any potential to participate in the appreciation of the Reference Asset and be willing to lose some or all of their principal at maturity.
·The notes will pay a Contingent Coupon on each Contingent Coupon Payment Date at the Contingent Interest Rate of 1.0583% per month (approximately 12.70% per annum) if the closing level of the Reference Asset on the applicable monthly Observation Date is greater than or equal to its Coupon Barrier Level. However, if the closing level of the Reference Asset is less than its Coupon Barrier Level on an Observation Date, the notes will not pay the Contingent Coupon for that Observation Date.
·Beginning on December 18, 2025, if on any Observation Date, the closing level of the Reference Asset is greater than its Call Level, the notes will be automatically redeemed. On the following Contingent Coupon Payment Date (the “Call Settlement Date"), investors will receive their principal amount plus the Contingent Coupon otherwise due. After the notes are redeemed, investors will not receive any additional payments in respect of the notes.
·The notes do not guarantee any return of principal at maturity. Instead, if the notes are not automatically redeemed, the payment at maturity will be based on the Final Level of the Reference Asset and whether the Final Level of that Reference Asset has declined from its Initial Level to below its Trigger Level on the Valuation Date (a “Trigger Event”), as described below.
·If the notes are not automatically redeemed and a Trigger Event has occurred, investors will lose 1% of the principal amount for each 1% decrease in the level of the Reference Asset from its Initial Level to its Final Level. In such a case, you will receive a cash amount at maturity that is less than the principal amount, together with the final Contingent Coupon, if payable.
·Investing in the notes is not equivalent to a direct investment in the Reference Asset.
·The notes will not be listed on any securities exchange.
·All payments on the notes are subject to the credit risk of Bank of Montreal.
·The notes will be issued in minimum denominations of $1,000 and integral multiples of $1,000.
·Our subsidiary, BMO Capital Markets Corp. (“BMOCM”), is the agent for this offering. See “Supplemental Plan of Distribution (Conflicts of Interest)” below.
·The notes will not be subject to conversion into our common shares or the common shares of any of our affiliates under subsection 39.2(2.3) of the Canada Deposit Insurance Corporation Act (the “CDIC Act”).

 

Terms of the Notes:

 

 Pricing Date:  June 17, 2025    Valuation Date:  July 20, 2026
 Settlement Date:  June 23, 2025    Maturity Date:  July 23, 2026

Specific Terms of the Notes:

 

Autocallable
Number
Reference
Asset
Ticker
Symbol
Initial
Level
Contingent
Interest Rate
Coupon
Barrier
Level*
Trigger
Level*
CUSIP Principal
Amount
Price to
Public
1
Agent’s
Commission
1
Proceeds to
Bank of
Montreal
1
5008  The American depositary receipts of Novo Nordisk A/S  NVO  $74.34  1.0583% per month (approximately 12.70% per annum)  $44.60, 60.00% of its Initial Level  $44.60, 60.00% of its Initial Level 06376EH62 $5,518,000.00 100%

2.15%

$118,637.00

97.85%

$5,399,363.00

1 The total “Agent’s Commission” and “Proceeds to Bank of Montreal” specified above reflect the aggregate amounts at the time Bank of Montreal established its hedge positions on or prior to the Pricing Date, which may have been variable and fluctuated depending on market conditions at such times. Certain dealers who purchased the notes for sale to certain fee-based advisory accounts may have foregone some or all of their selling concessions, fees or commissions. The public offering price for investors purchasing the notes in these accounts was between $978.50 and $1,000 per $1,000 in principal amount.

* Rounded to two decimal places.

Investing in the notes involves risks, including those described in the “Selected Risk Considerations” section beginning on page P-5 hereof, the “Additional Risk Factors Relating to the Notes” section beginning on page PS-6 of the product supplement, and the “Risk Factors” section beginning on page S-1 of the prospectus supplement and on page 8 of the prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these notes or passed upon the accuracy of this document, the product supplement, the prospectus supplement or the prospectus. Any representation to the contrary is a criminal offense. The notes will be our unsecured obligations and will not be savings accounts or deposits that are insured by the United States Federal Deposit Insurance Corporation, the Deposit Insurance Fund, the Canada Deposit Insurance Corporation or any other governmental agency or instrumentality or other entity.

On the date hereof, based on the terms set forth above, the estimated initial value of the notes is $964.18 per $1,000 in principal amount. However, as discussed in more detail below, the actual value of the notes at any time will reflect many factors and cannot be predicted with accuracy.

 

BMO CAPITAL MARKETS

 

   
 

 

Key Terms of the Notes:

 

Reference Asset: The American depositary receipts of Novo Nordisk A/S (ticker symbol "NVO"). See "The Reference Asset" below for additional information.
   
Contingent Coupons: If the closing level of the Reference Asset on an Observation Date is greater than or equal to its Coupon Barrier Level, a Contingent Coupon will be paid on the corresponding Contingent Coupon Payment Date at the Contingent Interest Rate, subject to the automatic redemption feature.
   
Contingent Interest Rate: 1.0583% per month (approximately 12.70% per annum), if payable. Accordingly, each Contingent Coupon, if payable, will equal $10.583 for each $1,000 in principal amount.
   
Observation Dates:1 Three trading days prior to each scheduled Contingent Coupon Payment Date.
   
Contingent Coupon Payment
Dates:1
Interest, if payable, will be paid on the 23rd day of each month (or, if such day is not a business day, the next following business day), beginning on July 23, 2025 and ending on the Maturity Date, subject to the automatic redemption feature.
   
Automatic Redemption: Beginning on December 18, 2025, if, on any Observation Date, the closing level of the Reference Asset is greater than its Call Level, the notes will be automatically redeemed. No further amounts will be owed to you under the Notes.
   
Payment upon Automatic
Redemption:
If the notes are automatically redeemed, then, on the Call Settlement Date, investors will receive their principal amount plus the Contingent Coupon otherwise due.
   
Call Settlement Date:1 If the notes are automatically redeemed, the Contingent Coupon Payment Date immediately following the relevant Observation Date.
   
Payment at Maturity:

If the notes are not automatically redeemed, the payment at maturity for the notes is based on the performance of the Reference Asset.

 

You will receive $1,000 for each $1,000 in principal amount of the note, unless a Trigger Event has occurred.

 

If a Trigger Event has occurred, you will receive at maturity, for each $1,000 in principal amount of your notes, a cash amount equal to:

 

$1,000 + [$1,000 x Percentage Change]

 

This amount will be less than the principal amount of your note, and may be zero.

 

You will also receive the final Contingent Coupon, if payable.

   
Trigger Event:2 A Trigger Event will be deemed to occur if the Final Level of the Reference Asset is less than its Trigger Level on the Valuation Date.
   
Percentage Change:

The quotient, expressed as a percentage, of the following formula:

 

(Final Level - Initial Level)
Initial Level

   
Initial Level:2 As set forth on the cover hereof.
   
Coupon Barrier Level:2 $44.60, which is 60.00% of the Initial Level (rounded to two decimal places).
   
Trigger Level:2 $44.60, which is 60.00% of the Initial Level (rounded to two decimal places).
   
Call Level:2 100% of the Initial Level.
   
Final Level: The closing level of the Reference Asset on the Valuation Date.
   
Pricing Date: June 17, 2025
   
Settlement Date: June 23, 2025
   
Valuation Date:1 July 20, 2026
   
Maturity Date:1 July 23, 2026

 

 2 
 

 

Physical Delivery Amount: We will only pay cash on the Maturity Date, and you will have no right to receive any shares of the Reference Asset.
   
Calculation Agent: BMOCM
   
Selling Agent: BMOCM

 

1 Subject to the occurrence of a market disruption event, as described in the accompanying product supplement.

 

2 As determined by the calculation agent and subject to adjustment in certain circumstances. See "General Terms of the Notes — Anti-dilution Adjustments to a Reference Asset that Is an Equity Security (Including Any ETF)" in the product supplement for additional information.

 

 3 
 

 

Additional Terms of the Notes

 

You should read this document together with the product supplement dated March 25, 2025, the prospectus supplement dated March 25, 2025 and the prospectus dated March 25, 2025. This document, together with the documents listed below, contains the terms of the notes and supersedes all other prior or contemporaneous oral statements as well as any other written materials including preliminary or indicative pricing terms, correspondence, trade ideas, structures for implementation, sample structures, fact sheets, brochures or other educational materials of ours or the agent. You should carefully consider, among other things, the matters set forth in Additional Risk Factors Relating to the Notes in the product supplement, as the notes involve risks not associated with conventional debt securities. We urge you to consult your investment, legal, tax, accounting and other advisers before you invest in the notes.

 

You may access these documents on the SEC website at www.sec.gov as follows (or if such address has changed, by reviewing our filings for the relevant date on the SEC website):

 

Product supplement dated March 25, 2025:
https://www.sec.gov/Archives/edgar/data/927971/000121465925004743/b324250424b2.htm

 

Prospectus supplement dated March 25, 2025 and prospectus dated March 25, 2025:
https://www.sec.gov/Archives/edgar/data/927971/000119312525062081/d840917d424b5.htm

 

Our Central Index Key, or CIK, on the SEC website is 927971. As used in this document, "we", "us" or "our" refers to Bank of Montreal.

 

 4 
 

 

Selected Risk Considerations

 

An investment in the notes involves significant risks. Investing in the notes is not equivalent to investing directly in the Reference Asset. These risks are explained in more detail in the “Additional Risk Factors Relating to the Notes” section of the product supplement.

 

Risks Related to the Structure or Features of the Notes

 

·Your investment in the notes may result in a loss. — The notes do not guarantee any return of principal. If the notes are not automatically redeemed, the payment at maturity will be based on the Final Level and whether a Trigger Event has occurred. If the Final Level is less than its Trigger Level, a Trigger Event will occur, and you will lose 1% of the principal amount for each 1% that the Final Level is less than the Initial Level. In such a case, you will receive at maturity a cash payment that is less than the principal amount of the notes and may be zero. Accordingly, you could lose your entire investment in the notes.
·You may not receive any Contingent Coupons with respect to your notes. — We will not necessarily make periodic interest payments on the notes. If the closing level of the Reference Asset on an Observation Date is less than its Coupon Barrier Level, we will not pay you the Contingent Coupon applicable to that Observation Date. If the closing level of the Reference Asset is less than its Coupon Barrier Level on each of the Observation Dates, we will not pay you any Contingent Coupons during the term of the notes, and you will not receive a positive return on the notes. Generally, this non-payment of any Contingent Coupons will coincide with a greater risk of principal loss on your notes.
·Your notes are subject to automatic early redemption. — We will redeem the notes if the closing level of the Reference Asset on any Observation Date is greater than its Call Level. Following an automatic redemption, you will not receive any additional Contingent Coupons and may not be able to reinvest your proceeds in an investment with returns that are comparable to the notes. Furthermore, to the extent you are able to reinvest such proceeds in an investment with a comparable return for a similar level of risk, you may incur transaction costs such as dealer discounts and hedging costs built into the price of the new notes.
·Your return on the notes is limited to the Contingent Coupons, if any, regardless of any appreciation in the value of the Reference Asset. — You will not receive a payment at maturity with a value greater than your principal amount plus the final Contingent Coupon, if payable. In addition, if the notes are automatically redeemed, you will not receive a payment greater than the principal amount plus the applicable Contingent Coupon, even if the Final Level exceeds the Call Level by a substantial amount. Accordingly, your maximum return on the applicable notes is limited to the potential return represented by the Contingent Coupons.
·Your return on the notes may be lower than the return on a conventional debt security of comparable maturity. — The return that you will receive on your notes, which could be negative, may be less than the return you could earn on other investments. The notes do not provide for fixed interest payments and you may not receive any Contingent Coupons over the term of the notes. Even if you do receive one or more Contingent Coupons and your return on the notes is positive, your return may be less than the return you would earn if you bought a conventional senior interest bearing debt security of ours with the same maturity or if you invested directly in the Reference Asset. Your investment may not reflect the full opportunity cost to you when you take into account factors that affect the time value of money.
·A higher Contingent Interest Rate or lower Trigger Level or Coupon Barrier Level may reflect greater expected volatility of the Reference Asset, and greater expected volatility generally indicates an increased risk of loss at maturity. — The economic terms for the notes, including the Contingent Interest Rate, Coupon Barrier Level and Trigger Level, are based, in part, on the expected volatility of the Reference Asset at the time the terms of the notes are set. “Volatility” refers to the frequency and magnitude of changes in the level of the Reference Asset. The greater the expected volatility of the Reference Asset as of the Pricing Date, the greater the expectation is as of that date that the closing level of the Reference Asset could be less than its Coupon Barrier Level on any Observation Date and that a Trigger Event could occur and, as a consequence, indicates an increased risk of not receiving a Contingent Coupon and an increased risk of loss, respectively. All things being equal, this greater expected volatility will generally be reflected in a higher Contingent Interest Rate than the yield payable on our conventional debt securities with a similar maturity or on otherwise comparable securities, and/or lower Trigger Level and/or Coupon Barrier Level than those terms on otherwise comparable securities. Therefore, a relatively higher Contingent Interest Rate may indicate an increased risk of loss. Further, a relatively lower Trigger Level and/or Coupon Barrier may not necessarily indicate that the notes have a greater likelihood of a return of principal at maturity and/or paying Contingent Coupons. You should be willing to accept the downside market risk of the Reference Asset and the potential to lose a significant portion or all of your initial investment.

 

Risks Related to the Reference Asset

 

·Owning the notes is not the same as owning shares of the Reference Asset or a security directly linked to the Reference Asset. — The return on your notes will not reflect the return you would realize if you actually owned shares of the Reference Asset or a security directly linked to the performance of the Reference Asset and held that investment for a similar period. Your notes may trade quite differently from the Reference Asset. Changes in the level of the Reference Asset may not result in comparable changes in the market value of your notes. Even if the level of the Reference Asset increases during the term of the notes, the market value of the notes prior to maturity may not increase to the same extent. It is also possible for the market value of the notes to decrease while the level of the Reference Asset increases. In addition, any dividends or other distributions paid on the Reference Asset will not be reflected in the amount payable on the notes.
·You will not have any shareholder rights and will have no right to receive any shares of the Reference Asset at maturity. — Investing in your notes will not make you a holder of any shares of the Reference Asset. Neither you nor any other holder or owner of the notes will have any voting rights, any right to receive dividends or other distributions, or any other rights with respect to the Reference Asset.
·No delivery of shares of the Reference Asset. — The notes will be payable only in cash. You should not invest in the notes if you seek to have the shares of the Reference Asset delivered to you at maturity.
·Single equity risk. — The level of the Reference Asset can rise or fall sharply due to factors specific to the Reference Asset and the issuer of the Reference Asset (the “Reference Asset Issuer”), such as stock price volatility, earnings, financial conditions, corporate, industry and regulatory developments, management changes and decisions and other events, as well as general market factors, such as general stock market volatility and levels, interest rates and economic and political conditions. We urge you to review financial and other information filed periodically with the SEC by the Reference Asset Issuer. We are not affiliated with the Reference Asset Issuer and are not responsible for the Reference Asset Issuer’s public disclosure of information, whether contained in SEC filings or otherwise. We have not undertaken any independent review or due diligence of the SEC filings of the Reference Asset Issuer or of any other publicly available information regarding the Reference Asset Issuer.

 

 5 
 

 

·You must rely on your own evaluation of the merits of an investment linked to the Reference Asset. — In the ordinary course of their businesses, our affiliates from time to time may express views on expected movements in the level of the Reference Asset. One or more of our affiliates have published, and in the future may publish, research reports that express views on the Reference Asset. However, these views are subject to change from time to time. Moreover, other professionals who deal in the markets relating to the Reference Asset at any time may have significantly different views from those of our affiliates. You are encouraged to derive information concerning the Reference Asset from multiple sources, and you should not rely on the views expressed by our affiliates.
Neither the offering of the notes nor any views which our affiliates from time to time may express in the ordinary course of their businesses constitutes a recommendation as to the merits of an investment in the notes.

 

General Risk Factors

 

·Your investment is subject to the credit risk of Bank of Montreal. — Our credit ratings and credit spreads may adversely affect the market value of the notes. Investors are dependent on our ability to pay any amounts due on the notes, and therefore investors are subject to our credit risk and to changes in the market’s view of our creditworthiness. Any decline in our credit ratings or increase in the credit spreads charged by the market for taking our credit risk is likely to adversely affect the value of the notes.
·Potential conflicts. — We and our affiliates play a variety of roles in connection with the issuance of the notes, including acting as calculation agent. In performing these duties, the economic interests of the calculation agent and other affiliates of ours are potentially adverse to your interests as an investor in the notes. We or one or more of our affiliates may also engage in trading of shares of the Reference Asset on a regular basis as part of our general broker-dealer and other businesses, for proprietary accounts, for other accounts under management or to facilitate transactions for our customers. Any of these activities could adversely affect the level of the Reference Asset and, therefore, the market value of, and the payments on, the notes. We or one or more of our affiliates may also issue or underwrite other securities or financial or derivative instruments with returns linked or related to changes in the performance of the Reference Asset. By introducing competing products into the marketplace in this manner, we or one or more of our affiliates could adversely affect the market value of the notes.
·Our initial estimated value of the notes is lower than the price to public. — Our initial estimated value of the notes is only an estimate, and is based on a number of factors. The price to public of the notes exceeds our initial estimated value, because costs associated with offering, structuring and hedging the notes are included in the price to public, but are not included in the estimated value. These costs include any underwriting discount and selling concessions, the profits that we and our affiliates expect to realize for assuming the risks in hedging our obligations under the notes and the estimated cost of hedging these obligations.
·Our initial estimated value does not represent any future value of the notes, and may also differ from the estimated value of any other party. — Our initial estimated value of the notes as of the date hereof is derived using our internal pricing models. This value is based on market conditions and other relevant factors, which include volatility of the Reference Asset, dividend rates and interest rates. Different pricing models and assumptions could provide values for the notes that are greater than or less than our initial estimated value. In addition, market conditions and other relevant factors after the Pricing Date are expected to change, possibly rapidly, and our assumptions may prove to be incorrect. After the Pricing Date, the value of the notes could change dramatically due to changes in market conditions, our creditworthiness, and the other factors set forth herein and in the product supplement. These changes are likely to impact the price, if any, at which we or BMOCM would be willing to purchase the notes from you in any secondary market transactions. Our initial estimated value does not represent a minimum price at which we or our affiliates would be willing to buy your notes in any secondary market at any time.
·The terms of the notes were not determined by reference to the credit spreads for our conventional fixed-rate debt. — To determine the terms of the notes, we used an internal funding rate that represents a discount from the credit spreads for our conventional fixed-rate debt. As a result, the terms of the notes are less favorable to you than if we had used a higher funding rate.
·Certain costs are likely to adversely affect the value of the notes. — Absent any changes in market conditions, any secondary market prices of the notes will likely be lower than the price to public. This is because any secondary market prices will likely take into account our then-current market credit spreads, and because any secondary market prices are likely to exclude all or a portion of any underwriting discount and selling concessions, and the hedging profits and estimated hedging costs that are included in the price to public of the notes and that may be reflected on your account statements. In addition, any such price is also likely to reflect a discount to account for costs associated with establishing or unwinding any related hedge transaction, such as dealer discounts, mark-ups and other transaction costs. As a result, the price, if any, at which BMOCM or any other party may be willing to purchase the notes from you in secondary market transactions, if at all, will likely be lower than the price to public. Any sale that you make prior to the Maturity Date could result in a substantial loss to you.
·Lack of liquidity. — The notes will not be listed on any securities exchange. BMOCM may offer to purchase the notes in the secondary market, but is not required to do so. Even if there is a secondary market, it may not provide enough liquidity to allow you to trade or sell the notes easily. Because other dealers are not likely to make a secondary market for the notes, the price at which you may be able to trade the notes is likely to depend on the price, if any, at which BMOCM is willing to buy the notes.
·Hedging and trading activities. — We or any of our affiliates have carried out or may carry out hedging activities related to the notes, including purchasing or selling shares of the Reference Asset, futures or options relating to the Reference Asset or other derivative instruments with returns linked or related to changes in the performance on the Reference Asset. We or our affiliates may also trade in the Reference Asset or instruments related to the Reference Asset from time to time. Any of these hedging or trading activities on or prior to the Pricing Date and during the term of the notes could adversely affect the payments on the notes.
·Many economic and market factors will influence the value of the notes. — In addition to the level of the Reference Asset and interest rates on any trading day, the value of the notes will be affected by a number of economic and market factors that may either offset or magnify each other, and which are described in more detail in the product supplement.

 

 6 
 

 

·Significant aspects of the tax treatment of the notes are uncertain. — The tax treatment of the notes is uncertain. We do not plan to request a ruling from the Internal Revenue Service or from any Canadian authorities regarding the tax treatment of the notes, and the Internal Revenue Service or a court may not agree with the tax treatment described herein.
The Internal Revenue Service has released a notice that may affect the taxation of holders of “prepaid forward contracts” and similar instruments. According to the notice, the Internal Revenue Service and the U.S. Treasury are actively considering whether the holder of such instruments should be required to accrue ordinary income on a current basis. While it is not clear whether the notes would be viewed as similar to such instruments, it is possible that any future guidance could materially and adversely affect the tax consequences of an investment in the notes, possibly with retroactive effect.
Please read carefully the section entitled "U.S. Federal Tax Information" herein, the section entitled "Supplemental Tax Considerations–Supplemental U.S. Federal Income Tax Considerations" in the accompanying product supplement, the section entitled "United States Federal Income Taxation" in the accompanying prospectus and the section entitled "Certain Income Tax Consequences" in the accompanying prospectus supplement. You should consult your tax advisor about your own tax situation.

 

 7 
 

 

Examples of the Hypothetical Payment at Maturity for a $1,000 Investment in the Notes

 

The following table illustrates the hypothetical payments on a note at maturity, assuming that the notes are not automatically redeemed. The hypothetical payments are based on a $1,000 investment in the note, a hypothetical Initial Level of $100.00, a hypothetical Trigger Level of $60.00 (60.00% of the hypothetical Initial Level), a hypothetical Call Level of $100.00 (100.00% of the hypothetical Initial Level), a range of hypothetical Final Levels and the effect on the payment at maturity.

 

The hypothetical examples shown below are intended to help you understand the terms of the notes. If the notes are not automatically redeemed, the actual cash amount that you will receive at maturity will depend upon the Final Level of the Reference Asset. If the notes are automatically redeemed prior to maturity, the hypothetical examples below will not be relevant, and you will receive on the applicable Call Settlement Date, for each $1,000 principal amount, the principal amount plus the applicable Contingent Coupon.

 

As discussed in more detail above, your total return on the notes will also depend on the number of Contingent Coupon Dates on which the Contingent Coupon is payable. It is possible that the only payments on your notes will be the payment, if any, due at maturity. The payment at maturity will not exceed the principal amount, and may be significantly less.

 

Hypothetical Final Level Hypothetical Final Level Expressed
as a Percentage of the Initial Level
Payment at Maturity (Excluding
Coupons)
$200.00 200.00% $1,000.00
$180.00 180.00% $1,000.00
$160.00 160.00% $1,000.00
$140.00 140.00% $1,000.00
$120.00 120.00% $1,000.00
$100.00 100.00% $1,000.00
$90.00 90.00% $1,000.00
$80.00 80.00% $1,000.00
$70.00 70.00% $1,000.00
$60.00 60.00% $1,000.00
$59.99 59.99% $599.90
$40.00 40.00% $400.00
$20.00 20.00% $200.00
$0.00 0.00% $0.00

 

 8 
 

 

U.S. Federal Tax Information

 

By purchasing the notes, each holder agrees (in the absence of a change in law, an administrative determination or a judicial ruling to the contrary) to treat each note as a pre-paid contingent income-bearing derivative contract for U.S. federal income tax purposes. In the opinion of our counsel, Mayer Brown LLP, it would generally be reasonable to treat the notes as pre-paid contingent income-bearing derivative contracts in respect of the Reference Asset for U.S. federal income tax purposes. However, the U.S. federal income tax consequences of your investment in the notes are uncertain and the Internal Revenue Service could assert that the notes should be taxed in a manner that is different from that described in the preceding sentence. Please see the discussion in the accompanying product supplement under "Supplemental Tax Considerations—Supplemental U.S. Federal Income Tax Considerations—Notes Treated as Investment Units Consisting of a Debt Portion and a Put Option, as Pre-Paid Contingent Income-Bearing Derivative Contracts, or as Pre-Paid Derivative Contracts—Notes Treated as Pre-Paid Contingent Income-Bearing Derivative Contracts," which applies to the notes.

 

 9 
 

 

Supplemental Plan of Distribution (Conflicts of Interest)

 

BMOCM will purchase the notes from us at a purchase price reflecting the commission set forth on the cover hereof. BMOCM has informed us that, as part of its distribution of the notes, it will reoffer the notes to other dealers who will sell them. Each such dealer, or each additional dealer engaged by a dealer to whom BMOCM reoffers the notes, will receive a commission from BMOCM, which will not exceed the commission set forth on the cover page.

 

Certain dealers who purchase the notes for sale to certain fee-based advisory accounts may forego some or all of their selling concessions, fees or commissions. The public offering price for investors purchasing the notes in these accounts may be less than 100% of the principal amount, as set forth on the cover page of this document. Investors that hold their notes in these accounts may be charged fees by the investment advisor or manager of that account based on the amount of assets held in those accounts, including the notes. 

 

We will deliver the notes on a date that is greater than one business day following the pricing date. Under Rule 15c6-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes more than one business day prior to the issue date will be required to specify alternative settlement arrangements to prevent a failed settlement. 

 

We own, directly or indirectly, all of the outstanding equity securities of BMOCM, the agent for this offering. In accordance with FINRA Rule 5121, BMOCM may not make sales in this offering to any of its discretionary accounts without the prior written approval of the customer. 

 

You should not construe the offering of the notes as a recommendation of the merits of acquiring an investment linked to the Reference Asset or as to the suitability of an investment in the notes. 

 

BMOCM may, but is not obligated to, make a market in the notes. BMOCM will determine any secondary market prices that it is prepared to offer in its sole discretion. 

 

We may use this pricing supplement in the initial sale of the notes. In addition, BMOCM or another of our affiliates may use this pricing supplement in market-making transactions in any notes after their initial sale. Unless BMOCM or we inform you otherwise in the confirmation of sale, this pricing supplement is being used by BMOCM in a market-making transaction.

 

For a period of approximately three months following issuance of the notes, the price, if any, at which we or our affiliates would be willing to buy the notes from investors, and the value that BMOCM may also publish for the notes through one or more financial information vendors and which could be indicated for the notes on any brokerage account statements, will reflect a temporary upward adjustment from our estimated value of the notes that would otherwise be determined and applicable at that time. This temporary upward adjustment represents a portion of (a) the hedging profit that we or our affiliates expect to realize over the term of the notes and (b) any underwriting discount and the selling concessions paid in connection with this offering. The amount of this temporary upward adjustment will decline to zero on a straight-line basis over the three-month period. 

 

The notes and the related offer to purchase notes and sale of notes under the terms and conditions provided herein do not constitute a public offering in any non-U.S. jurisdiction, and are being made available only to individually identified investors pursuant to a private offering as permitted in the relevant jurisdiction. The notes are not, and will not be, registered with any securities exchange or registry located outside of the United States and have not been registered with any non-U.S. securities or banking regulatory authority. The contents of this document have not been reviewed or approved by any non-U.S. securities or banking regulatory authority. Any person who wishes to acquire the notes from outside the United States should seek the advice or legal counsel as to the relevant requirements to acquire these notes.

 

British Virgin Islands. The notes have not been, and will not be, registered under the laws and regulations of the British Virgin Islands, nor has any regulatory authority in the British Virgin Islands passed comment upon or approved the accuracy or adequacy of this document. This pricing supplement and the related documents shall not constitute an offer, invitation or solicitation to any member of the public in the British Virgin Islands for the purposes of the Securities and Investment Business Act, 2010, of the British Virgin Islands.

 

Cayman Islands. Pursuant to the Companies Law (as amended) of the Cayman Islands, no invitation may be made to the public in the Cayman Islands to subscribe for the notes by or on behalf of the issuer unless at the time of such invitation the issuer is listed on the Cayman Islands Stock Exchange. The issuer is not presently listed on the Cayman Islands Stock Exchange and, accordingly, no invitation to the public in the Cayman Islands is to be made by the issuer (or by any dealer on its behalf). No such invitation is made to the public in the Cayman Islands hereby.

 

Dominican Republic. Nothing in this pricing supplement constitutes an offer of securities for sale in the Dominican Republic. The notes have not been, and will not be, registered with the Superintendence of Securities Market of the Dominican Republic (Superintendencia del Mercado de Valores), under Dominican Securities Market Law No. 249-17 (“Securities Law 249-17”), and the notes may not be offered or sold within the Dominican Republic or to, or for the account or benefit of, Dominican persons (as defined under Securities Law 249-17 and its regulations). Failure to comply with these directives may result in a violation of Securities Law 249-17 and its regulations.

 

Israel. This pricing supplement is intended solely for investors listed in the First Supplement of the Israeli Securities Law of 1968, as amended. A prospectus has not been prepared or filed, and will not be prepared or filed, in Israel relating to the notes offered hereunder. The notes cannot be resold in Israel other than to investors listed in the First Supplement of the Israeli Securities Law of 1968, as amended.

 

No action will be taken in Israel that would permit an offering of the notes or the distribution of any offering document or any other material to the public in Israel. In particular, no offering document or other material has been reviewed or approved by the Israel Securities Authority. Any material provided to an offeree in Israel may not be reproduced or used for any other purpose, nor be furnished to any other person other than those to whom copies have been provided directly by us or the selling agents.

 

 10 
 

 

Nothing in this pricing supplement or any other offering material relating to the notes, should be considered as the rendering of a recommendation or advice, including investment advice or investment marketing under the Law For Regulation of Investment Advice, Investment Marketing and Investment Portfolio Management, 1995, to purchase any note. The purchase of any note will be based on an investor’s own understanding, for the investor’s own benefit and for the investor’s own account and not with the aim or intention of distributing or offering to other parties. In purchasing the notes, each investor declares that it has the knowledge, expertise and experience in financial and business matters so as to be capable of evaluating the risks and merits of an investment in the notes, without relying on any of the materials provided.

 

Mexico. The notes have not been registered with the National Registry of Securities maintained by the Mexican National Banking and Securities Commission and may not be offered or sold publicly in Mexico. This pricing supplement and the related documents may not be publicly distributed in Mexico. The notes may only be offered in a private offering pursuant to Article 8 of the Securities Market Law.

 

Switzerland. This pricing supplement is not intended to constitute an offer or solicitation to purchase or invest in any notes. Neither this pricing supplement nor any other offering or marketing material relating to the notes constitutes a prospectus compliant with the requirements of articles 35 et seq. of the Swiss Financial Services Act ("FinSA")) for a public offering of the notes in Switzerland and no such prospectus has been or will be prepared for or in connection with the offering of the notes in Switzerland.

 

Neither this pricing supplement nor any other offering or marketing material relating to the notes has been or will be filed with or approved by a Swiss review body (Prüfstelle). No application has been or is intended to be made to admit the notes to trading on any trading venue (SIX Swiss Exchange or on any other exchange or any multilateral trading facility) in Switzerland. Neither this pricing supplement nor any other offering or marketing material relating to the notes may be publicly distributed or otherwise made publicly available in Switzerland.

 

The notes may not be publicly offered, directly or indirectly, in Switzerland within the meaning of FinSA except (i) in any circumstances falling within the exemptions to prepare a prospectus listed in article 36 para. 1 FinSA or (ii) where such offer does not qualify as a public offer in Switzerland, provided always that no offer of notes shall require the Issuer or any offeror to publish a prospectus pursuant to article 35 FinSA in respect to such offer and that such offer shall comply with the additional restrictions set out below (if applicable). The Issuer has not authorised and does not authorise any offer of notes which would require the Issuer or any offeror to publish a prospectus pursuant to article 35 FinSA in respect of such offer. For purposes of this provision "public offer" shall have the meaning as such term is understood pursuant to article 3 lit. g and h FinSA and the Swiss Financial Services Ordinance ("FinSO").

 

The notes do not constitute participations in a collective investment scheme within the meaning of the Swiss Collective Investment Schemes Act. They are not subject to the approval of, or supervision by, the Swiss Financial Market Supervisory Authority ("FINMA"), and investors in the notes will not benefit from protection under CISA or supervision by FINMA.

 

Prohibition of Offer to Private Clients in Switzerland - No Key Information Document pursuant to article 58 FinSA (Basisinformationsblatt für Finanzinstrumente) or equivalent document under foreign law pursuant to article 59 para. 2 FinSA has been or will be prepared in relation to the notes. Therefore, the following additional restriction applies: Notes qualifying as "debt securities with a derivative character" pursuant to article 86 para. 2 FinSO may not be offered within the meaning of article 58 para. 1 FinSA, and neither this pricing supplement nor any other offering or marketing material relating to such notes may be made available, to any retail client (Privatkunde) within the meaning of FinSA in Switzerland.

 

The notes may also be sold in the following jurisdictions, provided, in each case, any sales are made in accordance with all applicable laws in such jurisdiction:

 

·Barbados
·Bermuda

 

 11 
 

 

Additional Information Relating to the Estimated Initial Value of the Notes

 

Our estimated initial value of the notes on the date hereof that is set forth on the cover hereof, equals the sum of the values of the following hypothetical components:

 

·a fixed-income debt component with the same tenor as the notes, valued using our internal funding rate for structured notes; and 
·one or more derivative transactions relating to the economic terms of the notes. 

 

The internal funding rate used in the determination of the initial estimated value generally represents a discount from the credit spreads for our conventional fixed-rate debt. The value of these derivative transactions is derived from our internal pricing models. These models are based on factors such as the traded market prices of comparable derivative instruments and on other inputs, which include volatility, dividend rates, interest rates and other factors. As a result, the estimated initial value of the notes on the Pricing Date was determined based on the market conditions on the Pricing Date. 

 

 12 
 

 

The Reference Asset

 

We have derived the following information from publicly available documents. We have not independently verified the accuracy or completeness of the following information. We are not affiliated with the Reference Asset Issuer and the Reference Asset Issuer will have no obligations with respect to the notes. This document relates only to the notes and does not relate to the shares of the Reference Asset. Neither we nor any of our affiliates participates in the preparation of the publicly available documents described below. Neither we nor any of our affiliates has made any due diligence inquiry with respect to the Reference Asset in connection with the offering of the notes. There can be no assurance that all events occurring prior to the date hereof, including events that would affect the accuracy or completeness of the publicly available documents described below and that would affect the trading price of the shares of the Reference Asset, have been or will be publicly disclosed. Subsequent disclosure of any events or the disclosure of or failure to disclose material future events concerning the Reference Asset could affect the price of the shares of the Reference Asset on each Observation Date and on the Valuation Date, and therefore could affect the payments on the notes.

 

The selection of the Reference Asset is not a recommendation to buy or sell the shares of the Reference Asset. Neither we nor any of our affiliates make any representation to you as to the performance of the shares of the Reference Asset. Information provided to or filed with the SEC under the Exchange Act and the Investment Company Act of 1940 relating to the Reference Asset may be obtained through the SEC’s website at http://www.sec.gov.

 

We encourage you to review recent levels of the Reference Asset prior to making an investment decision with respect to the notes.

 

Novo Nordisk A/S is a healthcare company that engages in the discovery, development, manufacturing and marketing of pharmaceutical products. Information filed by the company with the SEC can be located by reference to its SEC file number: 333-82318, or its CIK Code: 0000353278. Its American Depositary Receipts are listed on the New York Stock Exchange under the ticker symbol “NVO.”

 

 13 
 

 

Validity of the Notes

 

In the opinion of Osler, Hoskin & Harcourt LLP, the issue and sale of the notes has been duly authorized by all necessary corporate action of the Bank in conformity with the Senior Indenture, and when this pricing supplement has been attached to, and duly notated on, the master note that represents the notes, the notes will have been validly executed and issued and, to the extent validity of the notes is a matter governed by the laws of the Province of Ontario, or the laws of Canada applicable therein, and will be valid obligations of the Bank, subject to the following limitations (i) the enforceability of the Senior Indenture may be limited by the Canada Deposit Insurance Corporation Act (Canada), the Winding-up and Restructuring Act (Canada) and bankruptcy, insolvency, reorganization, receivership, moratorium, arrangement or winding-up laws or other similar laws affecting the enforcement of creditors’ rights generally; (ii) the enforceability of the Senior Indenture may be limited by equitable principles, including the principle that equitable remedies such as specific performance and injunction may only be granted in the discretion of a court of competent jurisdiction; (iii) pursuant to the Currency Act (Canada) a judgment by a Canadian court must be awarded in Canadian currency and that such judgment may be based on a rate of exchange in existence on a day other than the day of payment; and (iv) the enforceability of the Senior Indenture will be subject to the limitations contained in the Limitations Act, 2002 (Ontario), and such counsel expresses no opinion as to whether a court may find any provision of the Senior Debt Indenture to be unenforceable as an attempt to vary or exclude a limitation period under that Act. This opinion is given as of the date hereof and is limited to the laws of the Provinces of Ontario and the federal laws of Canada applicable thereto. In addition, this opinion is subject to customary assumptions about the trustee’s authorization, execution and delivery of the Indenture and the genuineness of signatures and certain factual matters, all as stated in the letter of such counsel dated March 25, 2025, which has been filed as Exhibit 5.3 to Bank of Montreal’s Form 6-K filed with the SEC and dated March 25, 2025.

 

In the opinion of Mayer Brown LLP, when this pricing supplement has been attached to, and duly notated on, the master note that represents the notes, and the notes have been issued and sold as contemplated herein, the notes will be valid, binding and enforceable obligations of Bank of Montreal, entitled to the benefits of the Senior Indenture, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally, concepts of reasonableness and equitable principles of general applicability (including, without limitation, concepts of good faith, fair dealing and the lack of bad faith). This opinion is given as of the date hereof and is limited to the laws of the State of New York. Insofar as this opinion involves matters governed by the laws of the Province of Ontario, or the laws of Canada applicable therein, Mayer Brown LLP has assumed, without independent inquiry or investigation, the validity of the matters opined on by Osler, Hoskin & Harcourt LLP, Canadian legal counsel for the issuer, in its opinion expressed above. This opinion is subject to customary assumptions about the trustee’s authorization, execution and delivery of the Senior Indenture and the genuineness of signatures and to such counsel’s reliance on the Bank of Montreal and other sources as to certain factual matters, all as stated in the legal opinion of Mayer Brown LLP dated March 25, 2025, which has been filed with the SEC as an exhibit to a report on Form 6-K by the Bank of Montreal on March 25, 2025.

 

 

14

 

 

FAQ

What contingent coupon do the BMO notes pay?

They offer 1.0583 % per month (about 12.70 % per annum) whenever the Novo Nordisk ADR closes at or above $44.60 on an Observation Date.

When can the notes be automatically redeemed?

Starting 18 December 2025, if the ADR closes above its $74.34 Initial Level on any Observation Date, the notes are called at par plus the due coupon.

Is principal protected at maturity?

No. If the ADR closes below the $44.60 trigger level (60 % of Initial Level) on 20 July 2026, investors lose 1 % of principal for each 1 % decline.

Are the notes listed on an exchange?

No. The notes will not be listed, so liquidity depends on the dealer’s willingness to repurchase.

What is the estimated initial value compared with the issue price?

The estimated initial value is $964.18 per $1,000, roughly 3.6 % below the $1,000 issue price.

Who bears the credit risk of the product?

All payments rely on Bank of Montreal; the notes are unsecured, unsubordinated obligations of the issuer.
MicroSectors™ Energy 3X Leveraged ETN

NYSE:WTIU

WTIU Rankings

WTIU Latest News

WTIU Latest SEC Filings

WTIU Stock Data

1.50M
Commercial Banking
Commercial Banks, Nec
Link
Canada
TORONTO